First-line camrelizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A nationwide, retrospective real-world study. This is an ASCO Meeting Abstract from the ...
Comparative real-world survival and prescription patterns of darolutamide versus apalutamide in non-metastatic hormone-resistant prostate cancer. This is an ASCO Meeting Abstract from the 2026 ASCO ...
Biomarker testing identifies high-risk early-stage NSCLC patients for adjuvant chemotherapy, reducing recurrence risk by 78%. The AIM-HIGH study shows a 96% disease-free survival rate at 24 months ...
Immediate Instantaneous Wave-Free Ratio Guided Versus Deferred Cardiac Magnetic Resonance Imaging Guided Revascularization of Non-Culprit Lesions in Patients with Acute ST-Elevation Myocardial ...
Aortic stenosis affects millions of elderly people worldwide. TAVR is a minimally invasive procedure that allows a new valve to be inserted through a catheter, usually through a small incision in the ...
PuraPly® AM is a patent-protected product that is differentiated among all skin substitutes by combining a native, cross-linked collagen matrix with polyhexamethylene biguanide (PHMB) antimicrobial to ...
Richard T. Bryan, PhD, Wenyu Liu, PhD, Sarah J. Pirrie, MSc, Rashid Amir, FRCR, Jean Gallagher, Ana I. Hughes, MSc, Kieran P. Jefferson, FRCS, Allen Knight, MBA ...
Hosted on MSN
First clinical trial in MOGAD meets primary endpoint
The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results